Cerium oxide nanoparticles modulating the Parkinson's disease conditions: From the alpha synuclein structural point of view and antioxidant properties of cerium oxide nanoparticles

氧化铈纳米颗粒调节帕金森病症状:从α-突触核蛋白结构角度和氧化铈纳米颗粒的抗氧化特性出发

阅读:1

Abstract

Parkinson's and Alzheimer's disease is the main cause of dementia, which is associated with the progressive deterioration of the intelligence and senses. Free radicals are created during oxidative stress in cells, which are considered one of the destructive factors in neurodegenerative diseases. In this study, the antifibrillar and antioxidant properties of cerium oxide nanoparticles (CeO(2) NPs) were investigated experimentally and theoretically. The CeO(2) NPs were synthesized and analyzed to reveal the physicochemical and biological properties. The results showed that the CeO(2) NPs have unique properties with potent antioxidant activities. The experimental and computational studies showed that the CeO(2) NPs interact with the active site of Alpha-synuclein. The existence of hydrogen bonding between O atoms of CeO(2) NPs and N-H of adjacent acid amines and the equilibrium distances were confirmed by 1.751 (Leu100), 1.786 (Gln99) and 2.213 Å (Lys97). The minimum free energy binding of L-DOPA drug (as positive control) and CeO(2) NPs were negative, resulting interaction between compounds and protein. As a result, these compounds inhibited Alpha-synuclein protein aggregation. In addition, that CeO(2) NPs strongly binds with receptor by relative binding energy as compared with L-DOPA drug. These findings revealed that CeO(2) NPs prevent Alpha-synuclein fibrillation and can be applied as nano-drug against the Parkinson's disease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。